

TABLE OF CONTENTS

July 12, 2010

No. 2196

BUSINESS

- 1 Teijin to Create Its Own Marketing Network in China
- 2 Shionogi to Create Its Own Marketing Network in Asia
 - Shionogi Creates US Headquarters
- 3 Eisai Licenses Lorcaserin from Arena in the US
- 3 ASKA's Mid-Term Management Plan Calls For ¥48 Bil. Sales in FY2012
 - 100 Employees Invited to Early Retirement
- 4 Nippon Kayaku Aims at Doubling Pharma Sales to ¥100 Bil. in FY2015
- 4 AZ to Expand Production Capacity at Its Maibara Plant
- 5 *Koroshio* to Cancel 30% of Anti-Flu Vaccines from Novartis
- 6 Takeda Appoints Haruhiko Hirate as Corporate Officer
- 7 **BUSINESS NEWS IN BRIEF**
 - NanoCarrier Obtains Patent Related to Polymeric Micelles in Europe
 - Banyu, Schering-Plough Reorganize Sales, Marketing Structures
 - GSK, MTPC to Terminate Copromotion of Adair
- 7 **Survey**
 - RA Patients Highly Satisfied with Biologics Treatment: Pfizer

REGULATORY

- 8 17 New Drugs Recommended for Approval
- 8 PMDA Reduces Review Period to 19.2 M for Ordinary Products
 - PMDA to Simplify Face-to-Face Consultation Procedures
- 9 Effects of New Premium Must Be Verified: New *Chuikyo* Pricing Subcommittee Chairman
- 10 JPMA Calls on Its Members Not to Refer to Premium When Negotiating Prices
 - Using New Premium as Pretext to Increase Prices Is Shameful: Mr Yamamoto of JPA
- 11 Acute-Stage Hospitals Concerned about Increases in Drug Purchase Costs
 - Concerns Have Not Yet Become Generalized
- 12 Council Holds Hearing on Immunization Programs
- 12 **REGULATORY NEWS IN BRIEF**
 - Yakult Applies for XELOX Regimen for Colon Cancer
 - Pariet Approved for Non-Erosive GERD in Japan: Eisai
 - Janssen Applies for Golimumab for RA
 - Banyu Applies for Vorinostat for CTCL in Japan

- Joint Application Submitted for Acetaminophen Dosage Increase
- Feraheme Applied for Iron Deficiency Anemia in Europe: Takeda
- ZERIA to File NDA for Acotiamide in Japan This Fall
- Tasigna Approved in 1st-Line Therapy for Ph+CML in the US

GENERICS

- 15 Sawai Considers Entry into Biosimilars Business
- 15 Pfizer Considers Contract Manufacturing Generics in India

COMMENTARY

- 16 **Maurer's Healthcare Insight (123)**
 - The *Tako Tsubo* Factor: P. Reed Maurer

TOPICS

- Astellas Appoints Naoki Okamura as President of OSI Pharm.
- OD Tablet Tester Marketed by Nipro

R&D

- 18 Pfizer to Strengthen Drug Discovery Alliances in Japan
- 18 **R&D NEWS IN BRIEF**
 - Merck Serono Recommences PIII for Stimuvax in NSCLC
 - Kissei's KUC-7483 Fails to Meet Efficacy Endpoint
 - ASP1941 Fund to Reduce HbA1c in Japanese Patients in PII: Astellas
 - Omnaris HFA Meets Primary Endpoint for Efficacy in PIII: DSP
 - Hematide Shows Non-Inferiority in 4 PIII Trials Overseas: Takeda, Affymax
 - NDA for Anti-CCR4 Antibody to Be Filed Soon: Prof. Ueda

MEDICAL FACILITIES & NURSING CARE

- 20 Interim Analysis of PMS Data Confirms Favorable Safety Profile for Nexavar
- 20 Low-Dose SU Effective for Controlling Blood Glucose: JADEC Study
- 21 JUPITER Trial Data on Crestor Biased: Prof. Hamazaki
- 23 JMHA to Survey Drugs Purchased by Its Member Hospitals Every Year
- 21 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - Council Recommends Approval for 2 Advanced Therapies